Indoco Remedies Q4 FY26 Revenue Up 19% YoY

Indoco Remedies reported consolidated Q4 FY26 revenue growth of 18.8% YoY to ₹4,559 million, driven by a 94.6% surge in international formulations.
Standalone EBITDA margin improved significantly to 14.7% from 1% YoY, marking a return to profitability after six challenging quarters.
The company announced the hive-off of its Indian and African ophthalmic business to Sunway to focus on core therapeutic areas.
Management outlined plans to reduce debt by ₹140 crore in FY27 and expects continued growth in international markets from solid/oral and new liquid oral products.